Lipigon Pharmaceuticals AB
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
LPGO | ST
Overview
Corporate Details
- ISIN(s):
- SE0015382072
- LEI:
- 549300XPO40YR12SLY87
- Country:
- Sweden
- Address:
- Tvistevägen 48 C, 907 36 Umeå
- Website:
- https://lipigon.se/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Lipigon Pharmaceuticals AB is a clinical-stage pharmaceutical company specializing in lipid biology. The company focuses on developing novel therapeutics for diseases caused by disorders in the body's fat metabolism. Its lead drug candidate, Lipisense®, is in clinical development and designed to lower triglyceride levels through a unique mechanism of action, addressing a significant risk factor for cardiovascular disease. Founded in 2010 as a spin-off from Umeå University, Lipigon leverages 50 years of lipid research and proprietary technologies to target unmet medical needs in patients with lipid-related disorders.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Lipigon Pharmaceuticals AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Lipigon Pharmaceuticals AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Lipigon Pharmaceuticals AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-12-16 | Johan Living | Other | Buy | 260,000 | 51,688.00 SEK |
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
